share_log

Panbela Therapeutics | DEFA14A: Others

Panbela Therapeutics | DEFA14A: Others

Panbela Therapeutics | DEFA14A:其他
美股sec公告 ·  04/26 04:42
牛牛AI助理已提取核心訊息
On April 23, 2024, Panbela Therapeutics, Inc. entered into a material definitive agreement with Michael T. Cullen, the Chairman of the Board of Directors. The agreement involved the sale of one share of Series A Preferred Stock to Cullen for $10. The transaction was completed on the same day. This Preferred Stock grants 90,000,000 votes to Cullen, solely for voting on proposals to amend the company's certificate of incorporation regarding a reverse stock split of the common stock. The Preferred Stock is non-convertible, does not entitle the holder to dividends, and has no liquidation rights. It may be redeemed at the discretion of the Board or upon stockholder approval of a reverse stock split. On April 25, 2024, Nasdaq filed a Form 25 indicating the...Show More
On April 23, 2024, Panbela Therapeutics, Inc. entered into a material definitive agreement with Michael T. Cullen, the Chairman of the Board of Directors. The agreement involved the sale of one share of Series A Preferred Stock to Cullen for $10. The transaction was completed on the same day. This Preferred Stock grants 90,000,000 votes to Cullen, solely for voting on proposals to amend the company's certificate of incorporation regarding a reverse stock split of the common stock. The Preferred Stock is non-convertible, does not entitle the holder to dividends, and has no liquidation rights. It may be redeemed at the discretion of the Board or upon stockholder approval of a reverse stock split. On April 25, 2024, Nasdaq filed a Form 25 indicating the delisting of Panbela Therapeutics' common stock, which will take effect ten days post-filing. Consequently, the company has applied to list its common stock on the CBOE's US Equity Listings Tier II and will maintain its OTCQB listing under the symbol 'PBLA' in the interim. Due to the delisting, a special meeting initially scheduled for May 3, 2024, to vote on the reverse stock split has been postponed to May 28, 2024, with a new record date set for April 24, 2024. A new proxy statement will be prepared and mailed for the rescheduled meeting.
2024 年 4 月 23 日,Panbela Therapeutics, Inc. 與董事會主席邁克爾·卡倫簽訂了實質性的最終協議。該協議涉及以10美元的價格向卡倫出售一股A系列優先股。該交易於當天完成。該優先股向卡倫授予了9,000,000張選票,僅用於對修改公司關於普通股反向拆分的公司註冊證書的提案進行投票。優先股不可兌換,不賦予持有人分紅的權利,也沒有清算權。董事會可以自行決定贖回,也可以在股東批准反向股票拆分後兌換。2024年4月25日,納斯達克提交了25號表格,表明Panbela Therapeutics的普通股已退市,該表將在申報後十天生效。因此,該公司已申請在芝加哥期權交易所的...展開全部
2024 年 4 月 23 日,Panbela Therapeutics, Inc. 與董事會主席邁克爾·卡倫簽訂了實質性的最終協議。該協議涉及以10美元的價格向卡倫出售一股A系列優先股。該交易於當天完成。該優先股向卡倫授予了9,000,000張選票,僅用於對修改公司關於普通股反向拆分的公司註冊證書的提案進行投票。優先股不可兌換,不賦予持有人分紅的權利,也沒有清算權。董事會可以自行決定贖回,也可以在股東批准反向股票拆分後兌換。2024年4月25日,納斯達克提交了25號表格,表明Panbela Therapeutics的普通股已退市,該表將在申報後十天生效。因此,該公司已申請在芝加哥期權交易所的美國股票上市二級股票上市,並將在此期間維持其OTCQB上市,股票代碼爲 “PBLA”。由於退市,原定於2024年5月3日舉行的反向股票拆分投票的特別會議已推遲到2024年5月28日,創紀錄的日期定爲2024年4月24日。將爲重新安排的會議準備並郵寄一份新的委託書。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。